Yanting Sun, Xiaoliu Wu, Ming Zhu, Yuanying Zhang, Min Lv, Liling Dai, Jun Yu
{"title":"Gambogic acid and chloroquine synergistically induce cell death via increasing mitochondria damage in human <scp>NSCLC</scp> cells","authors":"Yanting Sun, Xiaoliu Wu, Ming Zhu, Yuanying Zhang, Min Lv, Liling Dai, Jun Yu","doi":"10.1002/prm2.12133","DOIUrl":"https://doi.org/10.1002/prm2.12133","url":null,"abstract":"Abstract Gambogic acid is a natural bioactive compound from the brownish resin of the Garcinia hanburyi trees, which has been shown to induce cell death of cancer cells with a synergistic effect together with other compounds. In the present study, we aim to investigate whether the combination of gambogic and chloroquine, one of the inhibitor of autophagy, could increase cell death in human NSCLC cells. As a result, gambogic acid and chloroquine synergistically suppress the growth of NSCLC cells (CI <0.9). Moreover, the combination of gambogic acid and chloroquine significantly promotes apoptosis than that either alone does. Mechanistically, the results demonstrate that gambogic acid increases PINK1 expression at mRNA and protein level, accompanied with downregulation of Tom20, suggesting the mitophagy process is activated. Both silencing PINK1 and treatment of chloroquine could inhibit mitophagy, therefore disrupting the clearance of damaged mitochondria. Thus, co‐treatment of gambogic acid and chloroquine results in an elevated level of ROS, which facilitates cell death. Taken together, our finding highlights that the synergistically inhibitory effect of gambogic acid and chloroquine on NSCLC cells is associated with the accumulation of mitochondrial damage.","PeriodicalId":504069,"journal":{"name":"Precision Medical Sciences","volume":"13 3","pages":"172-180"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prm2.12133","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147917479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Porous egg microparticles for controllable drug delivery and oncotherapy","authors":"Dan Yan, Wei Wang, ZhengZheng Xie","doi":"10.1002/prm2.12144","DOIUrl":"https://doi.org/10.1002/prm2.12144","url":null,"abstract":"Abstract Baicalein (BAI) extracted from Chinese herb has been proved to increase the sensitivity of tumor cells to gemcitabine (GEM) and effectively solve the problem of drug resistance of tumor cells. Nevertheless, intravenous administration often leads to intolerance of patients and side effects. In this paper, we introduced egg‐based porous microparticles for controllable drug delivery and oncotherapy, which avoided frequent intravenous administration. The interconnected porous structure endowed the microparticles with the capacity of loading sufficient drugs and releasing in a controllable way by adjusting the concentration and proportion of egg white and yolk. We have demonstrated that the cell viability of drug delivery system group was less than 50%, while the single drug group was more than 70%, which indicated that the co‐delivery of GEM and BAI could significantly reduce the proliferation of cells. These features indicated that the egg porous microparticles are ideal for controllable drug delivery and oncotherapy.","PeriodicalId":504069,"journal":{"name":"Precision Medical Sciences","volume":"14 1","pages":"46-53"},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prm2.12144","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147891574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fang Meng, Jiaru Hu, Jinhu Qiang, Qifeng Shi, Jing Ji, Zhenyu Li, Lu Li, Lei Lv, Shiqiang Zhang
{"title":"<scp>scRNA</scp>‐seq determines the characteristics of T cell marker genes to predict the prognosis of esophageal cancer","authors":"Fang Meng, Jiaru Hu, Jinhu Qiang, Qifeng Shi, Jing Ji, Zhenyu Li, Lu Li, Lei Lv, Shiqiang Zhang","doi":"10.1002/prm2.12130","DOIUrl":"https://doi.org/10.1002/prm2.12130","url":null,"abstract":"Abstract Esophageal cancer (EC) mainly includes two histological subtypes, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma, which is of high morbidity and mortality. With the continuous development of medical technology, the treatment of EC has been greatly improved, but its prognosis is still unfavorable. Recent single‐cell RNA‐sequencing (scRNA‐seq) is expected to bring breakthroughs in the treatment of EC. First, we identified T cell marker genes and generated signature by analyzing scRNA‐seq data from Expression Omnibus (GEO) database and TCGA database. Then, an immune prognostic model was constructed using the least absolute shrinkage and selection operator. We found that the survival rate of ESCC varied significantly among the low‐ and high‐risk groups. Two genes from T cell signature, DCPS and CYB5R3, were expressed in ESCC cells. Collectively, our study proposed a novel prognostic signature for ESCC patients based on T cell marker genes.","PeriodicalId":504069,"journal":{"name":"Precision Medical Sciences","volume":"13 2","pages":"107-117"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prm2.12130","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147885250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical analysis of 94 cases of ocular adnexal lymphomas","authors":"Yu‐ying Sun, Shu‐ai Luo, Chun‐yu Huang","doi":"10.1002/prm2.12125","DOIUrl":"https://doi.org/10.1002/prm2.12125","url":null,"abstract":"To investigate the imaging manifestations and pathological features of ocular adnexal lymphoma (OALs) in order to provide relevant information for ophthalmologists. A total of 94 patients with OALs were pathologically confirmed between August 2018 and July 2023, and their demographics, location, subtype, treatment, and prognosis were retrospectively studied. 94 patients with OALs were included in this study, of whom 28 were female (29.79%) and 66 were male (70.21%). The age of the patients ranged from 21 to 80 years, with a predominance of 50–60 years (60/94); monocular onset was common (90/94), and the most site of onset was orbital (74/94), followed by conjunctiva (12/94), eyelids (4/94), vitreous (3/94), and lacrimal gland (1/94). CT and MRI can show the involvement and extent of the lesions, and the pathology of the disease is characterized by mucosa‐associated lymphoid tissue marginal zone B‐cell lymphoma (72/94), diffuse large B‐cell lymphoma (10/94), T‐cell lymphoma (4/94), mantle cell lymphoma (2/94), Burkitt's lymphoma (2/94), small lymphocytic lymphoma (2/94), and follicular lymphoma (1/94). All patients received surgical treatment, 42 patients received local radiation therapy, 35 patients received chemotherapy, 13 patients received radiation therapy and chemotherapy successively, and 3 patients received comprehensive treatment. During the follow‐up, three patients relapsed, four died, one was lost to follow‐up, and the remaining patients had stable conditions. The majority of OALs are mucosa‐associated lymphoid tissue marginal zone B‐cell lymphomas (MALT) with an excellent prognosis. It mostly occurs in people over 50 years of age and most site of the onset is orbital.","PeriodicalId":504069,"journal":{"name":"Precision Medical Sciences","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140424869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Factors associated with the onset and survival of subsequent primary breast cancer in female non‐metastatic breast cancer survivors","authors":"Shunshun Liang, Rongwu Xiang, Shubing Jia, Sihan Zhou, Hongmiao Lian, YunChun Hu, Qian Cheng, Mingyi Zhao","doi":"10.1002/prm2.12122","DOIUrl":"https://doi.org/10.1002/prm2.12122","url":null,"abstract":"This study aimed to investigate the risk factors for the onset of subsequent primary breast cancer (SPBC) in women with a previous diagnosis of early‐stage breast cancer (BC) and to construct a prognostic prediction model for patients with SPBC. Using the Surveillance, Epidemiology, and End Results‐17 (SEER‐17) database, we conducted a retrospective cohort analysis on women with initial primary early‐stage BC from 2004 to 2015. Standardized incidence ratio (SIR) was calculated to determine the risk of subsequent primary cancer (SPC). A competing risk model was built to identify the risk factors for the onset of SPBC. And risk factors associated with breast cancer‐specific mortality in SPBC patients were evaluated and presented in the form of nomogram. Compared with the general population, the overall risk of SPC for all sites was significantly elevated in women with early‐stage BC (SIR = 1.21, 95% CI: 1.20–1.23), and breast is the most frequent site. Age, race and ethnicity, year of diagnosis, history of other tumors, histological type, surgery, radiation, chemotherapy, tumor size, positive lymph nodes numbers and ER status were independent risk factors (p < .05) for the onset of SPBC. A new prognosis nomogram demonstrated good discrimination after internal validation with a C‐index of 0.869 (95% CI: 0.859–0.880), and showed favorable consistency and clinical usefulness. The incidence of SPBC and prognosis of patients with SPBC were well estimated based on a large cohort. Our nomogram model had excellent prediction performance and could be a useful tool to predict prognosis.","PeriodicalId":504069,"journal":{"name":"Precision Medical Sciences","volume":"31 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139448583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
